Bristol's Orencia holds potential for juvenile arthritis

07/15/2008 | Yahoo!

Bristol-Myers Squibb Co.'s Orencia reduced flare-ups in children with rheumatoid arthritis by a third compared with those who took placebo, an Italian study found. Researchers said the drug can help pediatric patients who do not respond to an older medication, methotrexate, or tumor necrosis factor blockers, which include Johnson & Johnson's Remicade and Abbott Laboratories' Humira.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Chief Executive Officer
UCare Minnesota
Minneapolis, MN